All Posts

There’s a particular energy that surrounds a small, emerging biopharma company approaching its first drug launch. It’s a mix of excitement, fear, ambition, and sheer logistical overwhelm; equal parts moonshot  and tightrope . For regulatory advertising and promotional consultants, this territory is familiar. It is exhilarating, messy, and incredibly high stakes. And it never fails to reveal the same truth: scientific brilliance does not automatically translate into commercial

We’re no longer talking to the same people — or in the same way Traditional pharma advertising and promotional strategies that once targeted healthcare professionals, consumers, and payers now require an additional focus: AI platforms. The life sciences and healthcare industries are undergoing a transformative phase with the rise of Generative AI (GenAI). These AI systems, which include Large Language Models (LLMs) like ChatGPT and Gemini, create new content based on their va

I've been working in industry long enough to remember the infamous "14 Letters" that FDA sent out simultaneously to multiple pharmaceutical manufacturers in response to violative paid search ads. That was a day of infamy, and as luck would have it, I happened to work at a company that received 2, so I was able to see the impact first-hand when FDA decided to use enforcement tools to signify a shift in policy, or at least a firm reminder of the rules. As a Regulatory professio

As I was on my morning walk today enjoying the transition from Summer to Fall (which can be quite dramatic in Northern Michigan), I was struck by the first flashes of color in the grand maple trees and it got me thinking about change in general. There are two terms that are often used, albeit incorrectly, interchangeably.  According to Google Gemini: Early ADOPTER is the correct term for a person who embraces and uses a new product or technology shortly after it is released,